Royalty Pharma RPRX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's total current liabilities?
- Royalty Pharma (RPRX) reported total current liabilities of $535.68M in Q1 2026.
- How has Royalty Pharma's total current liabilities changed year-over-year?
- Royalty Pharma's total current liabilities decreased by 54.7% year-over-year, from $1.18B to $535.68M.
- What is the long-term trend for Royalty Pharma's total current liabilities?
- Over 5 years (2020 to 2025), Royalty Pharma's total current liabilities has grown at a 15.6% compound annual growth rate (CAGR), from $307.89M to $636.21M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.